Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune diseases. The drugs have the potential to become the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. The company has a lead project in myasthenia gravis as well as a second project in ANCA vasculitis. Toleranzia is listed on the Nasdaq First North Growth Market and backed by strongly committed renowned specialist investors.
Company Details
- Employees
- 17
- Founded
- -
- Address
- Arvid Wallgrens Backe 20, Gothenburg,411 26,sweden
- Phone
- +46-763-19 98 98
- in****@****zia.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- toleranzia.com
- Keywords
- IRLAB Therapeutics AB.
- HQ
- Gothenburg
Toleranzia Ab Questions
Toleranzia Ab's helpline number is +46-763-19 98 98
Toleranzia Ab's website is toleranzia.com
Toleranzia Ab's LinkedIn profile is https://se.linkedin.com/company/toleranzia-ab
Toleranzia Ab has
17 employees.
View email and phone details for 17
employees at Toleranzia Ab.
Toleranzia Ab's industry is
Pharmaceutical Manufacturing
Toleranzia Ab's top competitors are
Mendus Ab,
Synact Pharma,
Protein Production Sweden (Pps),
Frostpharma Ab,
Aquaporin A/s,
Vicore Pharma Ab,
Irlab Therapeutics Ab,
Ribocure Pharmaceuticals Ab,
Flerie,
Stayble Therapeutics.
Toleranzia Ab's support email address is info@toleranzia.com
Toleranzia Ab's categories are Pharmaceutical Manufacturing
Toleranzia Ab's founding year is 2011
